CardioExchange Archive

September 18th, 2014

Fellows: Want to Blog for CardioExchange at AHA.14?

Harlan M. Krumholz, MD, SM and John Ryan, MD

CardioExchange editors Harlan Krumholz and John Ryan are looking for fellows to blog for CardioExchange at the American Heart Association Scientific Sessions from November 15th through the 19th in Chicago. If you are interested in blogging, please contact us. We look forward to hearing from you!

---

November 18th, 2013

AHA.13 Headquarters

wpengine

CardioExchange is dedicated to bringing you the latest from AHA.13. Check out our coverage of the conference ─ and some of the great debates these posts have sparked ─ then tell us what you think! News: No Value for Renal-Artery Stenting in CORAL Controversy Erupts Over Accuracy of Cardiovascular Risk Calculator for Guidelines Replacement Versus Repair for […]

---

November 17th, 2013

Remaking the Heart: Stem Cells, Patches, Scaffolds, and More

Vimal Ramjee, MD

Which advance in regenerative cardiovascular biology has the best chance of being translated into a clinical treatment? A cardiology Fellow ponders cutting-edge science presentations at AHA.13.

---

November 7th, 2012

Science, with a Little Bit of Flash

Tariq Ahmad, MD, MPH

At a stirring Late-Breaking Clinical Trials session when researchers present possibly ground-breaking research, a fellow wonders what happens behind the scenes.

---

November 6th, 2012

Poster Sessions: Better to Present or Observe?

Eiman Jahangir, MD

A fellow presents his poster to a few people but finds more fulfillment in interacting with other poster presenters.

---

November 6th, 2012

Using the Internet to Learn from Leaders in Cardiology

Tariq Ahmad, MD, MPH

Fellows use apps, the Internet, and social media to make the most of AHA 12

---

November 6th, 2012

Late-Breaking Trials vs. Abstract Oral Sessions

Eiman Jahangir, MD

One fellow shares why he prefers to spend his time at AHA 2012 attending the abstract oral sessions.

---

November 16th, 2011

Evacetrapib – The New Wonder Drug?

Amit Shah, MD, MSCR

Impressive safety and efficacy data on evacetrapib—but it’s too early give odds on whether it’s a true wonder drug or a nightmare like its fellow CETP inhibitor, torceptrapib

---

November 16th, 2011

Was AIM HIGH a Hit or a Miss?

Reva Balakrishnan, MD, MPH

One of the best parts of this conference has been the opportunity to hear experts on the panels dissect and interpret the data following the presentations.

---

November 16th, 2011

AHA Lessons on Emotions and Heart Disease: Depressing Data but Hopeful Trends

Amit Shah, MD, MSCR

Several Cardiology Fellows who are attending AHA.11 this week are blogging together on CardioExchange.  The Fellows include Revathi Balakrishnan, Eiman Jahangir, John Ryan (moderator), and Amit Shah. Read the previous post here. Check back often to learn about the biggest buzz in Orlando. The many studies and sessions devoted to depression and heart disease at AHA — […]

---